November 16, 2020
Sonoran Biosciences Announces Issuance of Patent For SB Gel Extended-Release Technology
TEMPE, Ariz., Nov. 16, 2020 (GLOBE NEWSWIRE) — Sonoran Biosciences (“Sonoran” or the “Company”), a preclinical-stage pharmaceutical company developing innovative hospital based products for the treatment of surgical site infections and postoperative pain, announced today the issuance of the Company’s United States Patent “Temperature-Responsive Degradable Hydrogels.” The patent number is 11,173,210. The patent includes claims related to composition of polymer solutions and hydrogels, methods of preparation and mixing with active drugs, and methods of use.
About Sonoran Biosciences, Inc.
Sonoran Biosciences, Inc. is a privately held specialty pharmaceutical company developing sustained release formulations for the treatment of postoperative pain and surgical site infection (SSI). Sonoran’s products are based on its proprietary SB Gel, an injectable carrier that forms a solid gel in the body, releases drugs over multiple days, and dissolves after the drugs are released. Sonoran’s lead products are SBG004, a long-acting formulation of bupivacaine for postoperative pain, and SBG003, a fixed-dose combination of tobramycin and vancomycin for surgical site infection.
The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.